SOFINNOVA-PARTNERS
21.12.2023 18:07:32 CET | Business Wire | Press release
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the appointment of Andrew M. Weiss, an experienced leader in the medical devices industry whose ties to Sofinnova stretch back 20 years, as Venture Partner.
Mr. Weiss, who is based in San Francisco, will investigate global medical device investment opportunities across the Sofinnova Partners platform of strategies. He is currently an independent member on the boards of May Health and SafeHeal, two Sofinnova portfolio companies.
In 2013, Mr. Weiss was brought in as CEO to lead ReCor Medical, a company founded in 2009 by Mano Iyer, then an entrepreneur in residence at Sofinnova and now a partner in the Sofinnova medtech acceleration team. Mr. Weiss led ReCor, a pioneer in the use of ultrasound renal denervation to treat hypertension, as it scaled up to 175 employees, went through its clinical trials and was purchased by Otsuka Medical Devices in 2018. He also led preparations for ReCor’s US FDA PMA Approval, achieved in November of this year. Sofinnova Partners was the sole VC investor in ReCor at the time of the sale. Mr. Weiss retired from ReCor/Otsuka Medical Devices in April of 2023.
Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: “It's fantastic to have Andy back working with Sofinnova Partners. He is an outstanding leader with impeccable credentials in the medical devices sector. His performance at ReCor, a pioneering company, is legendary."
Mr. Weiss said: “I share Sofinnova’s passion for finding, nurturing and bringing new medical device therapies to patients. Having worked both informally and as a portfolio company CEO with Sofinnova for the past 20 years, I know that they have the best team, and are the gold-standard medical device venture group on a global basis. I am honored to become part of this team.”
Before he took the reins at ReCor, Mr. Weiss held leadership roles including President & CEO of Vital Images (acquired by Toshiba), VP & General Manager of the Medtronic Surgical Navigation Systems and Neurological Businesses, and President & CEO of CoAxia, which was sold to Zoll Medical.
Mr. Weiss is a graduate of the Massachusetts Institute of Technology with a degree in mechanical engineering and has an MBA from the Columbia University Graduate School of Business.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231221098742/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ares Management Prices European Direct Lending CLO II at Over €300 Million19.2.2026 18:25:00 CET | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the pricing of its second European Direct Lending Collateralized Loan Obligation, Ares European Direct Lending CLO II (“EDL CLO II”), at over €300 million. Consistent with the underlying composition of its predecessor, EDL CLO II is a diversified CLO comprised entirely of directly originated and actively managed loans issued by over 70 middle-market companies predominantly based in Western Europe and primarily operating in resilient industries. The instrument is weighted towards senior-secured floating rate loans and will be rated by S&P and KBRA. Ares believes EDL CLO II is among the first multi-currency middle-market CLOs in Europe. “We are pleased to successfully price our second European Direct Lending CLO in less than 12 months as we continue building on our nearly 20 years of corporate direct lending experience in Europe,” said Michael Dennis, Partner and Co-Head of
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis19.2.2026 18:00:00 CET | Press release
Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor (TNF) antagonists, found nearly half (47.3%) of randomized patients achieved primary endpoint of clinical remission at 54 weeksVedolizumab’s safety profile was generally consistent with its known safety profile in adultsResults were presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO) Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (UC), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 The results, presented at the 21st Congress of the European Crohn’
Andersen Consulting udvider sine kompetencer inden for data og analyse med Insight Consulting19.2.2026 17:06:00 CET | Pressemeddelelse
Andersen Consulting styrker sin platform gennem en samarbejdsaftale med Insight Consulting, der er en førende rådgivningsvirksomhed inden for data og digital strategi med tilstedeværelse i Sydafrika, Mozambique og Storbritannien. Insight Consulting tilbyder end-to-end-ydelser på tværs af den digitale værdikæde, herunder digital strategi, digital kompetenceudvikling, enterprise AI, skræddersyet softwareudvikling, dataintegration, analyse samt planlægning og forecasting. Virksomhedens tværfaglige teams kombinerer ekspertise inden for mennesker, teknologi og processer og sikrer, at effektiv forandringsledelse omfatter alle tre elementer. Virksomheden arbejder på tværs af brancher som detailhandel, logistik, oplevelsesbranchen, finans, fremstillingsindustrien, rejsebranchen, landbrug, transport og sundhed. "Samarbejdet med Andersen Consulting giver os adgang til et bredere globalt fodaftryk og avancerede metoder, samtidig med at vi kan bidrage med vores regionale indsigt og ekspertise inde
Visa Renews Partnership Across Red Bull Formula One Teams19.2.2026 15:00:00 CET | Press release
Long‑term renewal deepens Visa’s presence across Red Bull F1 Teams with enhanced branding, fan access and client experiences Renewed partnership to expand support of Oracle Red Bull Racing and Visa Cash App Racing Bulls Visa (NYSE: V) today announced a multi‑year renewal and expansion of its global partnership with Red Bull F1 Team’s Oracle Red Bull Racing and Visa Cash App Racing Bulls. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219542270/en/ Building on the groundbreaking partnership launched in 2024, the renewed agreement reinforces Visa’s commitment to one of the world’s fastest‑growing sports, while introducing significant new branding rights, enhanced hospitality assets and immersive experiential opportunities across both teams. Visa will also continue as a Title Partner of both Visa Cash App Racing Bulls Formula One Team and its F1 Academy Programme, further strengthening Visa’s presence on and off the grid. “T
Project B Taps Fashion Industry Veteran William Kim as Chief Lifestyle Officer19.2.2026 15:00:00 CET | Press release
Global basketball platform merges elite sport with fashion, design, and culture Project B, an elite global women’s and men’s basketball grand prix built for a new generation of athletes and fans, today announced the appointment of William Kim as Chief Lifestyle Officer. In this strategic role, Kim will lead Project B’s premium lifestyle business across merchandise, brand collaborations, and cultural partnerships as Project B expands across Europe, Asia, and the Americas to create the most premium cultural platform in global sport. “We are building a model designed for 2030 and beyond,” said Kim. “It starts with creating exceptional products. We’re sourcing the highest quality natural fibers for every moment in an athlete’s day and offering those same collections to the broader fan community. From design to supply chain to final consumer experience, we are operating with the same discipline and control as a luxury house, overseeing product, distribution, and brand experience holisticall
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom